Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;71(7):841-9.
doi: 10.1093/gerona/glw090. Epub 2016 May 21.

Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island

Affiliations
Review

Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island

Sebastian I Arriola Apelo et al. J Gerontol A Biol Sci Med Sci. 2016 Jul.

Abstract

Rapamycin (sirolimus) is a macrolide immunosuppressant that inhibits the mechanistic target of rapamycin (mTOR) protein kinase and extends lifespan in model organisms including mice. Although rapamycin is an FDA-approved drug for select indications, a diverse set of negative side effects may preclude its wide-scale deployment as an antiaging therapy. mTOR forms two different protein complexes, mTORC1 and mTORC2; the former is acutely sensitive to rapamycin whereas the latter is only chronically sensitive to rapamycin in vivo. Over the past decade, it has become clear that although genetic and pharmacological inhibition of mTORC1 extends lifespan and delays aging, inhibition of mTORC2 has negative effects on mammalian health and longevity and is responsible for many of the negative side effects of rapamycin. In this review, we discuss recent advances in understanding the molecular and physiological effects of rapamycin treatment, and we discuss how the use of alternative rapamycin treatment regimens or rapamycin analogs has the potential to mitigate the deleterious side effects of rapamycin treatment by more specifically targeting mTORC1. Although the side effects of rapamycin are still of significant concern, rapid progress is being made in realizing the revolutionary potential of rapamycin-based therapies for the treatment of diseases of aging.

Keywords: Intermittent rapamycin; Lifespan; Mouse; Rapamycin analogs.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Theoretical model of rapamycin regulation of lifespan by mTOR signaling. Rapamycin acutely inhibits mTORC1, while chronic administration also inhibits mTORC2 in the majority of tissues. Intermittent administration of rapamycin in the form of single acute doses (eg, 2mg/kg of rapamycin every 5 days) more precisely targets mTORC1 (45). Repression of mTORC1 promotes longevity through pathways that likely include the inhibition of S6K1, protein translation, and increased autophagy. Conversely, mTORC2 inhibition results in metabolic dysfunction and decreases the lifespan of male mice through an as yet undetermined mechanism.

References

    1. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28:721–726. - PubMed
    1. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 1977;55:48–51. - PubMed
    1. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol. 1990;144:251–258. - PubMed
    1. Singh K, Sun S, Vézina C. Rapamycin (AY-22,989), a new antifungal antibiotic II. Mechanism of action. J Antibiot. 1979;32:630–645. - PubMed
    1. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces II. Immunosuppressive effect of FK-506 in vitro. J Antibiot. 1987;40:1256–1265. - PubMed

MeSH terms

Substances